SAN FRANCISCO, CA—Scientists at the Gladstone Institute of Neurological Disease (GIND) in San Francisco have discovered a new strategy to prevent memory deficits in a mouse model of Alzheimer's disease.
SAN FRANCISCO, CA—Alzheimer's disease is an extremely complicated disease. Several proteins seem to be involved in its cause and progression.
SAN FRANCISCO, CA—Scientists at the Gladstone Institute of Neurological Disease (GIND) have uncovered new approaches to reduce toxic proteins in Alzheimer's disease (AD) and other neurodegenerative diseases. The results might lead to new treatments for these diseases.
SAN FRANCISCO, CA—Amyloid beta (Αβ) proteins, widely thought to cause Alzheimer's disease, block the transport of vital cargoes inside brain cells.
SAN FRANCISCO, CA—The Gladstone Institutes and the international pharmaceutical company H. Lundbeck A/S have announced a collaborative research agreement to study and identify therapeutic candidates for neurological diseases.
SAN FRANCISCO, CA—Scientists at the Gladstone Institute of Neurological Disease (GIND) and Stanford University have shown how key circuits in the brain control movement.
SAN FRANCISCO, CA—Stimulating the growth of new neurons to replace those lost in Alzheimer's disease (AD) is an intriguing therapeutic possibility. But will the factors that cause AD allow the new neurons to thrive and function normally?
SAN FRANCISCO, CA—The J. David Gladstone Institutes announced that it has received a major grant from the W.M. Keck Foundation in Los Angeles to establish the Keck Program for Striatal Physiology and Pathophysiology, which will study the origins of movement disorders associated with neurological diseases such as Parkinson's and Huntington's diseases.
SAN FRANCISCO, CA—Scientists from the Gladstone Institute of Neurological Disease (GIND), UCSF, and Stanford have discovered that a certain type of collagen, collagen VI, protects brain cells against amyloid-beta (Aβ) proteins, which are widely thought to cause Alzheimer's disease.